Radiolabelling rituximab with (99m)Tc in three steps procedure.

Autor: Fontan C; Radiopharmacy, University Hospital, Toulouse, France.; The Cancer Research Center of Toulouse, Toulouse, France., Bezombes C; The Cancer Research Center of Toulouse, Toulouse, France., Salabert AS; UMR 825, INSERM, Toulouse, France., Costes J; The Cancer Research Center of Toulouse, Toulouse, France., Lopez R; UMR 825, INSERM, Toulouse, France., Fournie JJ; The Cancer Research Center of Toulouse, Toulouse, France., Avet-Loiseau H; The Cancer Research Center of Toulouse, Toulouse, France., Coulais Y; Nuclear medicine, University Hospital, Toulouse, France., Payoux P; UMR 825, INSERM, Toulouse, France., Tafani M; UMR 825, INSERM, Toulouse, France.
Jazyk: angličtina
Zdroj: Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2015 Jun 15; Vol. 58 (7), pp. 274-80. Date of Electronic Publication: 2015 May 27.
DOI: 10.1002/jlcr.3283
Abstrakt: Lymphomas are the most frequent haematological malignancy. In non-Hodgkin's lymphomas (NHL), more than 90% of tumor cells express the cluster of differentiation (CD) 20 antigen. At the end of frontline therapy, the evaluation of remission is based on computed tomography (CT) and positron emission tomography coupled with computer tomography (PET/CT) with [(18)F]-fluorodeoxyglucose ([(18)F]FDG). Unfortunately, these techniques are not specific and cannot distinguish residual active tumor from inflammation. The aim of this study was to develop a specific radiotracer of NHL CD 20+ cells for clinical applications. The radiolabelling technique presented, based on the use of tricarbonyl compound, does not include an antibody reduction because this step could damage the protein. Actually, rituximab, an anti-CD 20 chimeric antibody used for the treatment of these NHL, was radiolabelled with Isolink® (99m)Tc-tricarbonyl compound in a three-step procedure without using a specific antibody reducer. Radiolabelling yield was greater than 97%. In vitro experiments showed a conservation of antibody integrity. In vivo experiments using Single-photon emission computed tomography/CT showed significant tumor targeting 24 h after injection of the radiotracer. It was consequently possible to develop an immunoradiolabelling method to specifically detect the residual disease. As this procedure is fast, reproducible and gentle, it will be possible to comply with Good Manufacturing Practices.
(Copyright © 2015 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: